Isolation and Structure Elucidation, Molecular Docking Studies of Screlotiumol from Soil Borne Fungi Screlotium rolfsii and their Reversal of Multidrug Resistance in Mouse Lymphoma Cells

  • Ahmad, Bashir (Center of Biotechnology and Microbiology, University of Peshawar) ;
  • Rizwan, Muhammad (Center of Biotechnology and Microbiology, University of Peshawar) ;
  • Rauf, Abdur (Department of Geology, University of Swabi) ;
  • Raza, Muslim (State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology) ;
  • Azam, Sadiq (Center of Biotechnology and Microbiology, University of Peshawar) ;
  • Bashir, Shumaila (Department of Pharmacy, University of Peshawar) ;
  • Molnar, Joseph (Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged) ;
  • Csonka, Akos (Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged) ;
  • Szabo, Diana (Department of Oto-Rhino-Laryngology and Head-Neck Surgery, Faculty of Medicine, University of Szeged)
  • Published : 2016.06.01


A new compound namely (13-(3,3-dihydroxypropyl)-1,6-dihydroxy-3,4-dihydro-1H-isochromen-8(5H)-one (1) was isolated from an ethyl acetate extract of the borne fungi Screlotium rolfsii. Its chemical structure was elucidated by spectroscopic analysis. Screlotiumol 1 were evaluated for their effects on the reversion of multidrug resistant (MDR) mediated by P-glycoprotein (P-gp) of the soil borne fungi. The multidrug resistant P-glycoprotein is a target for chemotherapeutic drugs in cancer cells. In the present study rhodamine-123 exclusion screening test on human mdr1 gene transfected mouse gene transfected L5178 and L5178Y mouse T-cell lymphoma which showed excellent MDR reversing effect in a dose dependent manner against mouse T-lymphoma cell line. Moreover, molecular docking studies of compound-1 also showed better results as compared with the standard. Therefore the preliminary results obtained from this study suggest that screlotiumol 1 could be used as a potential agent for the treatment of cancer.


  1. Assaraf YG (2006). The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resistance Updates, 9, 227-46.
  2. Berman HM, Westbrook J, Feng Z, et al (2000). The protein data bank. Nucleic acids Res, 28, 235-42.
  3. Bihorel S, Camenisch G, Lemaire M, et al (2007). Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharmaceutical Res, 24, 1720-8.
  4. Cole S, Bhardwaj G, Gerlach J, et al (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science-new York Then Washington, 258, 1650.
  5. Cornwell MM, Pastan I, Gottesman MM (1987). Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biological Chemistry, 262, 2166-70.
  6. DeLano WL (2002). PyMOL. delano scientific, san carlos, CA, 700.
  7. Germann UA, Pastan I, Gottesman MM (1993). P-glycoproteins: mediators of multidrug resistance. Seminars Cell Biol, Elsevier, 4, 63-76.
  8. Gottesman MM, Ambudkar SV (2001). Overview: ABC transporters and human disease. J Bioenergetics Biomembranes, 33, 453-8.
  9. Gottesman MM, Fojo T, Bates SE (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer, 2, 48-58.
  10. Guex N, Peitsch MC (1997). SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modeling. Electrophoresis, 18, 2714-23.
  11. Hanwell MD, Curtis DE, Lonie DC, et al (2012). Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. J. Cheminformatics, 4, 17.
  12. He SM, Li R, R Kanwar J, et al (2011). Structural and functional properties of human multidrug resistance protein 1 (MRP1/ ABCC1). Current Med Chem, 18, 439-81.
  13. Hsu KC, Chen YF, Lin SR, et al (2011). iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC bioinformatics, 12, 33.
  14. Jara GE, Vera DMA, Pierini AB (2013). Binding of modulators to mouse and human multidrug resistance P-glycoprotein. A computational study. J Molecular Graphics and Modelling, 46, 10-21.
  15. Jones P, George A (2004). The ABC transporter structure and mechanism: perspectives on recent research. Cellular Molecular Life Sciences CMLS, 61, 682-99.
  16. Leonard GD, Fojo T, Bates SE (2003). The role of ABC transporters in clinical practice. Oncologist, 8, 411-24.
  17. Li XQ, Li J, Shi SB, et al (2008). Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatinbased chemotherapy. International J Biological Markers, 24, 230-7.
  18. Li Z, Wan H, Shi Y, et al (2004). Personal experience with four kinds of chemical structure drawing software: review on ChemDraw, ChemWindow, ISIS/Draw, and Chem Sketch. J Chemical Information Computer Sciences, 44, 1886-90.
  19. Lopez D, Martinez-Luis S (2014). Marine natural products with P-glycoprotein inhibitor properties. Marine Drugs, 12, 525-46.
  20. Rauf A, Uddin G, Siddiqui BS, et al (2015). A rare class of new dimeric naphthoquinones from diospyros lotus have multidrug reversal and antiproliferative effects. Frontiers Pharmacol, 6, 293.
  21. Rauf A, Uddin G, Raza M, et al (2016). Reversal of multidrug resistance in mouse lymphoma cells by extracts and flavonoids from pistacia integerrima. Asian Pac J Cancer Prev, 17, 51-5.
  22. Rauf A, Uddin G, Raza M, et al (2016). Reversal of multidrug resistance and computational studies of pistagremic acid isolated from pistacia integerrima. Asian Pac J Cancer Prev.
  23. Rauf A, Khan R, Raza M, et al (2015a). Suppression of inflammatory response by chrysin, a flavone isolated from Potentilla evestita Th. Wolf. In silico predictive study on its mechanistic effect. Fitoterapia, 103, 129-35.
  24. Rauf A, Saleem M, Uddin G, et al (2015b). Phosphodiesterase-1 Inhibitory Activity of Two Flavonoids Isolated from Pistacia integerrima JL Stewart Galls. Evidence-Based Complementary and Alternative Med, 2015.
  25. Rauf A, Uddin G, Khan H, et al (2015c). Anti-tumour-promoting and thermal-induced protein denaturation inhibitory activities of ${\beta}$-sitosterol and lupeol isolated from Diospyros lotus L. Natural Product Res, 1-3.
  26. Robey RW, Polgar O, Deeken J, et al (2007). ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Reviews, 26, 39-57.
  27. Sakamoto A, Matsumaru T, Yamamura N, et al (2013). Quantitative expression of human drug transporter proteins in lung tissues: analysis of regional, gender, and interindividual differences by liquid chromatography– tandem mass spectrometry. J Pharmaceutical Sciences, 102, 3395-406.
  28. Sarkadi B, Homolya L, Szakacs G, et al (2006). Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiological reviews, 86, 1179-236.
  29. Szabo D, Molnar J (1997). The role of stereoselectivity of chemosensitizers in the reversal of multidrug resistance of mouse lymphoma cells. Anticancer Res, 18, 3039-44.
  30. Szakacs G, Paterson JK, Ludwig JA, et al (2006). Targeting multidrug resistance in cancer. Nature reviews Drug Discovery, 5, 219-34.
  31. Turner G (2000). Exploitation of fungal secondary metabolites old and new. Microbiology Today, 27, 118-121.
  32. Trott O, Olson AJ (2010). Auto dock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Computational Chemistry, 31, 455-61.
  33. Visualizer DS (2005). Accelrys software inc. Discovery Studio Visualizer, 2.
  34. Wallace AC, Laskowski RA, Thornton JM (1995). LIGPLOT: a program to generate schematic diagrams of protein-ligand

Cited by

  1. sp. vol.19, pp.10, 2017,